Search Results
Mar 04, 2026, 07:00 ET PK CONSUMER HEALTH ANNOUNCES THE ACQUISITION OF HEALTHAID, A LEADING UK VMS PLAYER
Furthermore, PK continues to strengthen its management structure, unlock synergies and invest in its brands, setting the company up for continued growth. Next to organic growth initiatives, PK continues to actively pursue M&A opportunities throughout Europe.Yvan Vindevogel, Chairman of PK Consumer
More news about: Avista Healthcare Partners
Mar 04, 2026, 02:00 ET Fapon Biopharma to Present Next-Generation CD3/TCR VHH TCE Platform at 19th Annual European Life Sciences CEO Forum
translational timelines. The platform has already successfully completed evaluation demonstrating superior efficacy and safety as well as predictable PK/PD in mouse and NHP studies.With superior CMC profiles and flexibility for multi-valent formatting, Fapon Biopharma is seeking strategic partners
More news about: Fapon Biopharma
Mar 03, 2026, 07:19 ET Natural Grocers® Softens the Spring Forward with Savings and Sleep-Smart Support
Melatonin 3 mg Time Release ($8.99/100 tab)Perfect Food Bars®, Protein Bars ($13.19/8 ct)Nixie® Organic Sparkling Waters ($4.79/8 pk)Boiron® Sleepcalm ($8.99/60 tab){N}power members will also get 20% off all packaged coffee and teas (clip coupon in mobile app).[vi]
More news about: Natural Grocers by Vitamin Cottage, Inc.
Mar 02, 2026, 10:29 ET XtalPi's AI + Robotics Platform Powers First Clinical Milestone for ReviR's Rare Neurological Drug RTX-117
(VWM)ReviR has dosed the first participant in a Phase 1 trial of RTX-117, initially evaluating safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) in healthy participantsMilestone marks the clinical entry of a potential first-in-class therapy
More news about: XtalPi
Mar 02, 2026, 09:00 ET ReviR Therapeutics Announces First Participant Dosed in Phase 1 Study and Secures CDE Clearance for Two Orphan Indications in China, Supporting Future U.S. Expansion Strategy
Phase 1 study is a randomized, double-blind, placebo-controlled, dose-escalation trial designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of RTX-117 in healthy participants, supporting the transition into subsequent clinical trials for patients with CMT and VWM.Advancing
More news about: ReviR Therapeutics
Mar 02, 2026, 07:00 ET AAON Reports Fourth Quarter and Full Year 2025 Results
1-888-880-3330. To access the listen-only webcast, please register at https://app.webinar.net/X2DbRx9Pk8v. On the next business day following the call, a replay of the call will be available on the company's website at
More news about: AAON
Feb 27, 2026, 10:24 ET Sun Pharma Showcases Data Across its Dermatology & Immunology Portfolio at 2026 Winter Clinical Miami
WINLEVI cream.Hypothalamic-pituitary-adrenal (HPA) axis suppression may occur during or after treatment with WINLEVI. In the pharmacokinetics (PK) trial, HPA axis suppression was observed in 1/20 (5%) of adult subjects and 2/22 (9%) of adolescent subjects at Day 14. All subjects returned to normal
More news about: Sun Pharma
Feb 25, 2026, 07:06 ET Zimmer Biomet to Release New Data, Highlight Key Innovations at American Academy of Orthopaedic Surgeons Annual Meeting
Recovery Curves in Total Knee Arthroplasty. The Journal of Arthroplasty. 2024;doi:10.1016/j.arth.2024.07.03913 Cushner FD, Sculco PK, Long WJ. The Talking Knee Is a Reality: What Your Knee Can Tell You After Total Knee Arthroplasty. J OrthopaedicExperience and Innovation. 2022;202214 Cushner
More news about: Zimmer Biomet Holdings, Inc.
Feb 25, 2026, 06:00 ET IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
Phase 1 dose escalation trial to determine safety, tolerability and PK of IDE034Potential as a monotherapy and in combination with proprietary PARG inhibitor, IDE161B7H3/PTK7 co-expressed in 30-40% of multiple solid tumor types, including lung, breast, ovarian and
More news about: IDEAYA Biosciences, Inc.
Feb 24, 2026, 13:40 ET Cinema Lenses Market to Reach USD 2,288.4 Million by 2032 as High-Resolution Content Demand Surges - Credence Research Inc.
More original series, documentaries, and branded content require cinema-grade visuals.For example, Sony Corporation's CineAlta lens system (SCL-PK6-F) provides six Super 35mm lenses from 20mm to 135mm with T2.0 apertures, certified for 4K capture. These lenses are widely used in streaming productions
More news about: Credence Research Inc.
Feb 24, 2026, 07:07 ET Natural Grocers® Celebrates Colorado With Three-Day Event, Mar. 3-5, 2026
Bobo's® Blueberry Fig Bars (5 pk). This beloved brand was established in 2003 when founder Beryl Stafford and her daughter "Bobo" baked oat bars that soon became a Boulder, CO café favorite.
More news about: Natural Grocers by Vitamin Cottage, Inc.
Feb 23, 2026, 16:05 ET BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
HighlightsInnovationAccelerated development of BMN 333, BioMarin's long-acting C-type natriuretic peptide (CNP), with Phase 1 PK data exceeding targeted free CNP exposure levels, reflecting its potential to become the new standard of care in achondroplasia.Advanced five
More news about: BioMarin Pharmaceutical Inc.
Feb 17, 2026, 15:14 ET UNCG, SparkNC and Guilford County Schools launch landmark partnership to prepare students for technology careers
County Schools is the third-largest district in North Carolina and among the largest of more than 14,000 in the United States. GCS serves nearly 67,000 PK-12 students at 121 schools. With approximately 9,800 employees, GCS works in partnership with parents, businesses, colleges and the community to deliver
More news about: University of North Carolina Greensboro
Feb 17, 2026, 11:00 ET FDA Approves FILKRI™ (filgrastim-laha), Accord BioPharma's Biosimilar to NEUPOGEN® (filgrastim)
studies in healthy adults, with pharmacokinetics (PK)/pharmacodynamics (PD) assessed in one study and safety and immunogenicity evaluated in both, compared with reference product NEUPOGEN. These studies demonstrated the biosimilarity in PD and PK parameters between FILKRI and NEUPOGEN and showed
More news about: Accord BioPharma
Feb 17, 2026, 08:00 ET FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month
NCT05498428) is an open-label Phase 2 study evaluating the efficacy, safety, and pharmacokinetics (PK) of first-line SC amivantamab (administered via manual injection) combined with LAZCLUZE® and/or chemotherapy in patients with EGFR-mutated
More news about: Johnson & Johnson
Feb 15, 2026, 19:10 ET CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial
features a multi-cohort, parallel expansion design to evaluate the efficacy, safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of CS2009 as monotherapy and combination regimens. The study comprises 15 monotherapy and combination therapy cohorts across 9
More news about: CStone Pharmaceuticals
Feb 12, 2026, 19:00 ET Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer
delivers a high payload of effective drugs to tumors. The highly hydrophilic linker design contributes to its excellent biophysical and pharmacokinetic (PK) properties, while the hydrophobic payload enhances its bystander effect, targeting adjacent antigen-low or negative tumor cells. IBI354 exhibits extremely
More news about: Innovent Biologics
Feb 11, 2026, 16:16 ET Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
well as daily oral dosing, weekly oral dosing, or placebo. The objectives of the study are to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of VK2735 under these various dosing regimens. Exploratory endpoints will assess change in body weight from baseline, as well as change in body
More news about: Viking Therapeutics, Inc.
Feb 10, 2026, 08:15 ET 100 Reasons to Celebrate: IXL Honors the Teachers Powering Today's Classrooms
IXLCurrently used by 17 million students and 96 of the top 100 U.S. school districts, IXL is an all-inclusive educational platform providing a comprehensive PK-12 curriculum, instructional resources, actionable analytics and a state-of-the-art assessment suite. Available in more than 120 languages, IXL's end-to-end
More news about: IXL Learning
Feb 06, 2026, 11:47 ET Winner, Winner: IXL Celebrates an Award-Filled 2025
literacy head-onIXL also collected its ninth CODiE Award after winning Best English Language Arts Instructional Solution for Grades PK - 8. The honor comes as schools are seeking new ways to elevate historically low reading scores.IXL offers a powerful solution to improve literacy
More news about: IXL Learning
Feb 06, 2026, 08:00 ET Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology
announced to have completed first patient dosing in patients with locally advanced and metastatic solid tumors, aiming to evaluate safety, tolerability, PK/PD characteristics, and preliminary efficacy.In addition to advancing its internal pipeline, Insilico Medicine and its global partners
More news about: Insilico Medicine
Feb 05, 2026, 15:55 ET intelliSPEC Announces Kash Mohammed as President to Lead Platform Evolution
Technological University."We are excited to welcome Kash to the intelliSPEC leadership team," said Stewart Records, Chief Executive Officer of PK Companies. "His experience and vision will be critical as we expand intelliSPEC into a scalable industrial intelligence platform that delivers long-term
More news about: intelliSPEC
Feb 04, 2026, 16:33 ET /C O R R E C T I O N -- PointsKash Inc./
R R E C T I O N – PointsKash Inc./ In the news release, PointsKash Inc. Engages Plaid to Power Secure, Seamless Onboarding and Bank Verification for PK Pay, issued 02-Feb-2026 by PointsKash Inc. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release
More news about: PointsKash Inc.
Feb 03, 2026, 10:00 ET Inductive Bio Wins World's Largest ADMET Prediction Competition, Advancing the State of the Art in Real-World Drug Discovery AI
reliably guide programs towards development candidates, even in challenging and novel chemical space."Inductive's Beacon ADMET and PK models are trained on one of the industry's largest and most diverse ADMET datasets and engineered with proprietary fine-tuning technology that adapts
More news about: Inductive Bio, Inc.
Feb 03, 2026, 08:49 ET Cartwheel Becomes Nation's Largest School Telehealth Provider Following Exceptional Growth and Major New Investment
tackling youth mental health. A-Street, which led the round, is a privately sponsored, multi-stage investment fund focused on backing and scaling innovative PK–12 solutions that improve student learning and achievement. The round included participation from new investors Citi Impact Fund, Britebound, and American
More news about: Cartwheel